What is Zacks Research’s Estimate for SBC Q1 Earnings?

SBC Medical Group Holdings Incorporated (NASDAQ:SBC) – Stock analysts at Zacks Research issued their Q1 2026 earnings per share (EPS) estimates for SBC Medical Group in a report released on Monday, April 6th. Zacks Research analyst M. Marin expects that the company will post earnings of $0.09 per share for the quarter. The consensus estimate for SBC Medical Group’s current full-year earnings is $5.02 per share. Zacks Research also issued estimates for SBC Medical Group’s Q2 2026 earnings at $0.12 EPS, Q3 2026 earnings at $0.13 EPS, Q4 2026 earnings at $0.12 EPS and FY2026 earnings at $0.46 EPS.

SBC Medical Group (NASDAQ:SBC) last released its quarterly earnings results on Friday, March 27th. The company reported $0.14 earnings per share for the quarter, topping analysts’ consensus estimates of $0.13 by $0.01. SBC Medical Group had a return on equity of 20.76% and a net margin of 29.37%.The company had revenue of $39.57 million during the quarter, compared to analysts’ expectations of $45.19 million.

A number of other equities research analysts also recently commented on the company. BTIG Research assumed coverage on SBC Medical Group in a research report on Friday, March 6th. They issued a “buy” rating and a $8.00 price objective for the company. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of SBC Medical Group in a research report on Friday, March 27th. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $8.50.

SBC Medical Group Stock Performance

NASDAQ SBC opened at $4.53 on Tuesday. SBC Medical Group has a fifty-two week low of $2.97 and a fifty-two week high of $5.75. The stock has a market cap of $464.69 million, a price-to-earnings ratio of 9.24 and a beta of 0.99. The business has a fifty day moving average of $4.13 and a 200-day moving average of $4.03. The company has a quick ratio of 5.06, a current ratio of 3.78 and a debt-to-equity ratio of 0.13.

Institutional Investors Weigh In On SBC Medical Group

A number of hedge funds and other institutional investors have recently made changes to their positions in SBC. Geode Capital Management LLC purchased a new stake in shares of SBC Medical Group in the second quarter valued at $455,000. Millennium Management LLC purchased a new stake in SBC Medical Group during the third quarter valued at about $219,000. New York State Common Retirement Fund purchased a new stake in SBC Medical Group during the second quarter valued at about $104,000. Williams & Novak LLC purchased a new stake in SBC Medical Group during the fourth quarter valued at about $65,000. Finally, XTX Topco Ltd purchased a new stake in SBC Medical Group during the second quarter valued at about $64,000. Hedge funds and other institutional investors own 60.82% of the company’s stock.

Insider Activity at SBC Medical Group

In other news, CEO Yoshiyuki Aikawa sold 4,422,900 shares of SBC Medical Group stock in a transaction on Friday, March 6th. The stock was sold at an average price of $2.12, for a total value of $9,376,548.00. Following the completion of the sale, the chief executive officer owned 861,600 shares of the company’s stock, valued at $1,826,592. The trade was a 83.70% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 89.47% of the stock is currently owned by corporate insiders.

SBC Medical Group Company Profile

SBC Medical Group, Inc is a publicly traded healthcare management services company listed on the Nasdaq under the ticker SBC. The company specializes in supporting in-office ancillary service providers by offering a suite of administrative and operational solutions designed to streamline practice management and enhance revenue performance. Its core mission is to help physician practices, imaging centers and other ancillary service providers focus on patient care while outsourcing complex back-office functions.

The company’s primary offerings include revenue cycle management, medical billing and coding, compliance oversight and transcription services.